Sign in: Staff/Students
New research, published in Nature Scientific Reports, conducted by the University and partners highlights effective methods for identifying a common side effect in children receiving drug treatments for Cystic fibrosis.
The genetic disorder, cystic fibrosis (CF) is characterised by secondary bacterial lung infections, often by a specific resistant bacteria, Pseudomonas aeruginosa. Antibiotics known as aminoglycosides have good efficacy against this bacteria and are often used to treat these infections.
However, aminoglycosides are potentially damaging to the kidneys. Despite risk reduction strategies, current or recent aminoglycoside exposure is strongly associated with acute kidney injury (AKI) in children with CF.
Current methods for assessing kidney injury rely on the measurement of serum creatinine, a measure of kidney filtration. Unfortunately this method only highlights injury once significant damage has already occurred. This is particularly dangerous for children.
To identify patients at increased risk of kidney damage there is a need for the development of improved biomarkers that not only reflect the site of toxicity, but can identify damage at an earlier stage than currently possible.
To help identify biomarkers, researchers from the Universities of Liverpool and University College London, recruited more than 150 children and young adults up to 20 years of age with a confirmed diagnosis of CF. The participants provided urine samples for measurement of specific proteins, KIM-1 and NGAL, at regular outpatient appointments, and before, during and after exposure to clinically-indicated treatment with anaminoglycoside.
The researchers found that the concentrations of both KIM-1 and NGAL increased during exposure to an aminoglycoside. These increases occurred in the absence of increases in serum creatinine, and therefore likely represent renal damage without loss of function, commonly termed ‘subclinical AKI’. The baseline (before treatment) concentration of KIM-1 increased with cumulative lifetime aminoglycoside exposure, suggesting it may also identify chronic renal damage.
Useful and non-invasive
The study was led by Dr Steve McWilliam a National Institute of Health Research Academic Clinical Lecturer in Paediatric Clinical Pharmacology from the University of Liverpool’s Institute of Translational Medicine based at Alder Hey Children’s NHS Foundation Trust.
Of the study Dr McWilliam said: “Our research shows that KIM-1 may be a useful, non-invasive, biomarker of acute and chronic kidney damage associated with exposure to aminoglycosides in patients with CF, but its clinical utility needs to be further evaluated in prospective studies.”
The full paper, entitled “Urinary Biomarkers of Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin”, can be found here.
You must be logged in to post a comment.
All recent news
‘Moth motorways’ could help resist climate change impact
Free access to the Sports Centre, 23 May – 1 June
Making the most of library resources
Developing a next-generation therapy for knee osteoarthritis
Careers support for final year students and graduates
‘𝗠𝗼𝘁𝗵 𝗺𝗼𝘁𝗼𝗿𝘄𝗮𝘆𝘀’ 𝗰𝗼𝘂𝗹𝗱 𝗵𝗲𝗹𝗽 𝗿𝗲𝘀𝗶𝘀𝘁 𝗰𝗹𝗶𝗺𝗮𝘁𝗲 𝗰𝗵𝗮𝗻𝗴𝗲 𝗶𝗺𝗽𝗮𝗰𝘁.
New research by @LivUni @UniofReading @Rothamsted & @savebutterflies predicts the movement of British moth species in a changing climate.
Absolutely, @DivockOrigi is a Liverpool legend!
Teammate @JHenderson spoke about Origi's legacy at the club and also the city through his support of our @LivUni Divock Origi Scholarships (@LivEchonews): https://www.liverpoolecho.co.uk/sport/football/football-news/jordan-henderson-divock-origi-liverpool-24012741 https://twitter.com/LFC/status/1527592848345944066
"There has been nothing to point to Sars-Cov-2 being associated with this illness, far less being a cause. There is a stronger association with adenovirus and associated virus, which remain under investigation," says @LivUni_IVES Prof Calum Semple. https://www.telegraph.co.uk/news/2022/05/19/childrens-hepatitis-cases-have-peaked-doctors-study-genetic/